spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Wickham Laboratories will be on Stand 8 at the 24th Annual Pharmig Conference in the Nottingham Belfry Hotel, November 16th & 17th

Wickham Laboratories Limited

Pharmig is a non-profit organisation dedicated to facilitating discussion on the latest research in pharmaceutical microbiology

Pharmig is a non-profit organisation dedicated to facilitating discussion on the latest research and trends in the field of pharmaceutical microbiology. This year’s speakers include delegates from Public Health England and several top pharma companies presenting on topics such as:
  • Microbiological Monitoring and Control in Sterile Compounding;
  • The Use of Rapid Microbiological Methods;
  • Bioburden Control in the Manufacture of Non-sterile Drug Products; and
  • The Potential Impact of Brexit on Pharmaceuticals and Biopharmaceuticals
These are just a few of the key items to be discussed at this year’s conference and we look forward to an exciting programme as well as the usual networking opportunities with clients and colleagues on Stand 8 in the main exhibition area.
phone +44 (0)1329 226600
email marketing@wickhamlabs.co.uk
web www.wickhamlabs.co.uk/
email Hoeford Point, Barwell Lane, Gosport, Hampshire, PO13 0AU, United Kingdom
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Fifth Annual Peptides Congress: Registration Now Open

Join us at the forefront of industry innovation at the 5th Annual Peptides Congress, 16-17 April 2018 in London to shape the future of industry discussion. With over 700 peptides in clinical trials and an increasing industry focus on biologics, now more than ever is the time to focus on this revolutionary field!
More info >>


White Papers

Driving ROI: The Case for Investing in Contract & Site Regulatory Document Management Services

DrugDev

With tight timelines and complicated regulatory documentation requirements, getting a clinical trial up and running quickly is easier said than done. Key milestones can be achieved only after the successful negotiation of clinical trial agreements and completion of essential regulatory documents. Many clinical trials are hindered by inefficient, labor-intensive processes. Prolonged, inefficient activation can hamper investigator satisfaction and, ultimately, have a negative bottom-line impact for sponsors and CROs. In addition, the Sunshine Act is heightening the importance of financial disclosure in clinical trials. Without a robust financial disclosure strategy, sponsors cannot ensure that physician self-reported financial disclosure data are aligned with the payment data being reported through the Sunshine Act, increasing financial and regulatory risk.
More info >>

Industry Events

Clinical Trial Supply Forum 2018

22-24 January 2018, London, UK

In the constantly changing environment of Clinical Trial Supply, cost efficiency, end to end visibility, logistics and managing complex pipelines are STILL crucial elements that need addressing!
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement